$CBAY new volume climb upper bollie $2.79 Nasdaq
Post# of 87
(Total Views: 564)
Posted On: 02/17/2017 3:13:28 PM
$CBAY new volume climb upper bollie $2.79
Nasdaq CM
Website
10-Q 11/9/16
100% x 100% Strong Buy
Last ten trades
Stock Technical Analysis
Low float
Shares Outstanding 28.63M
Float 21.83M
% Held by Insiders 5.27%
% Held by Institutions 30.00%
Shares Short 353.06k
Short Ratio 0.45
Short % of Float 1.52%
Shares Short (prior month) 542.88k
News
and filings
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its key clinical development candidates comprise MBX-8025, a selective agonist that is in a third Phase II clinical trial in patients with primary biliary cholangitis; and Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The companys product candidate also includes MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
Nasdaq CM
Website
10-Q 11/9/16
100% x 100% Strong Buy
Last ten trades
Stock Technical Analysis
Low float
Shares Outstanding 28.63M
Float 21.83M
% Held by Insiders 5.27%
% Held by Institutions 30.00%
Shares Short 353.06k
Short Ratio 0.45
Short % of Float 1.52%
Shares Short (prior month) 542.88k
News
and filings
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its key clinical development candidates comprise MBX-8025, a selective agonist that is in a third Phase II clinical trial in patients with primary biliary cholangitis; and Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The companys product candidate also includes MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
(0)
(0)